Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Policy & Advocacy
    • Health Equity
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in Trial
    • Volunteer
    • Events
    • Resources
  • Store
    • Learning
    • Apparel
    • Accessories
    • Bookshop
    • 7 Principles
Login
  • Donate
0

MDMA-Assisted Therapy

Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial

The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
January 5, 2023

Database in Phase 3 Trial of MDMA-Assisted Therapy for PTSD (MAPP2) Locked and Finalized

Since the final participant for this MAPP2 was treated on November 17, 2022, the database has been locked and is being analyzed. This study is our second Phase 3 trial of MDMA-assisted therapy for posttraumatic …
November 22, 2022

Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed (MAPP2)

MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
November 17, 2022

Enrolling: Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

Our Bronx VA study site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with …
September 21, 2022

Five Participants Enrolled in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

As of August 8, 2022, a total of five participants have been enrolled and the Bronx VA site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study …
August 8, 2022

First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three …
July 19, 2022

First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe

On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience …
July 18, 2022

MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations

The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System …
June 29, 2022

An Open-Label Feasibility and Safety Study of MDMA-Assisted Group Therapy for the Treatment of Posttraumatic Stress Disorder in Veterans (MPG1) Response to Continued Clinical Hold

On May 23, 2022, MAPS submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the concerns outlined in the continued partial clinical hold for MAPS-sponsored Study MPG1. …
May 23, 2022

Screening Begins in Phase 2 MDMA-Assisted Therapy Study of Participants with PTSD in Berlin and London

The MAPS Europe team is delighted to announce that screening of participants for our open-label Phase 2 study of MDMA-assisted therapy for PTSD has begun at the Charité – Universitätsmedizin Berlin …
May 11, 2022

MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD

FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
May 9, 2022

One Subject Treated, Four Subjects Evaluated in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

As of early May, one subject has been treated and four subjects are being evaluated for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted …
May 4, 2022

Posts navigation

Page 1 … Page 10 Older Posts
Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Health Equity
    • Policy & Advocacy
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up



  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2022 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Proudly powered by WordPress. Hosted by Pressable.